Lactam substituted imidazopyridazine IL-17A modulators and uses thereof
By providing an IL-17A modulator compound or a salt thereof with a structure of formula (I), the injection and high cost problems of existing IL-17A biological agents are solved, and effective IL-17A regulation and oral convenience are achieved.
CN119654325APending Publication Date: 2025-03-18DICE ALPHA INC
2 Cites 0 Cited by
Patent Information
- Application Number
- CN202380054652.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-19
- Filing Date
- 2023-05-19
- Publication Date
- 2025-03-18
AI Technical Summary
Technical Problem
Existing IL-17A biologics require injection and have high entry costs, limiting the availability of patients, and oral small molecule regulators lack the efficacy of approved biologics.
Method used
A compound represented by the structure of formula (I) or a pharmaceutically acceptable salt thereof is provided for the regulation of IL-17A, which is selected from the group consisting of 5- to 6-membered heteroaryl and C3-6 carbocyclic rings and carries specific substituents for use as a regulator of IL-17A.
Benefits of technology
This compound or salt can effectively regulate IL-17A, provide oral convenience, and have a low entry cost, achieving a therapeutic effect similar to that of approved biological agents.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure provides lactam-substituted imidazopyridazine compounds of Formula (I), (II), (II-a), (II-a), (III), (IV), (IV-a), and (IV-b) or pharmaceutical compositions thereof for modulating IL-17A. These compounds are useful in the treatment of inflammatory conditions such as psoriasis. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art